Bolt Biotherapeutics, Inc.

8-K · bolt-20260611.htm iXBRL

0001641281 2025-05-27 2025-05-27

 UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 WASHINGTON, D.C. 20549
  
 FORM 8-K
  
 CURRENT REPORT
 Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 Date of Report (Date of earliest event reported): June 10, 2026

  
  
 BOLT BIOTHERAPEUTICS, INC.
 (Exact name of Registrant as Specified in Its Charter)
  
  

 Delaware

 001-39988

 47-2804636

 (State or Other Jurisdiction
of Incorporation)

 (Commission File Number)

 (IRS Employer
Identification No.)

  

  

  

  

  

 900 Chesapeake Drive

  

 Redwood City , California

  

 94063

 (Address of Principal Executive Offices)

  

 (Zip Code)

  

 Registrant’s Telephone Number, Including Area Code: (650) 665-9295

  

 Not Applicable

 (Former Name or Former Address, if Changed Since Last Report)
  
 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 ☐

 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 ☐

 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 ☐

 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 ☐

 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 Securities registered pursuant to Section 12(b) of the Act:

Title of each class

  

 Trading
Symbol(s)

  

Name of each exchange on which registered

 Common Stock, par value $0.00001 per share

  

 BOLT

  

 The Nasdaq  Capital Market

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 Emerging growth company ☒
 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
  
  

  
 Item 5.07 Submission of Matters to a Vote of Security Holders.
 On June 10, 2026, Bolt Biotherapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”) to consider and vote on the three proposals set forth below, each of which is described in greater detail in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 28, 2026. A total of 1,921,567 shares of the Company's common stock were entitled to vote as of April 22, 2026, the record date for the Annual Meeting, of which 877,358 shares were represented in person or by proxy at the Annual Meeting. Proxies for the Annual Meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition of management’s solicitation.
 a. The following director nominees were elected to serve as Class II members of the Company’s board of directors until the Company’s 2029 Annual Meeting of Stockholders, or until their respective successor is duly elected and qualified, or until their respective death, resignation or removal:

 Nominee

  

 Votes For

  

  

 Votes Withheld

  

  

 Broker Non-Votes

  

 William P. Quinn

  

  

 349,358

  

  

  

 52,117

  

  

  

 475,883

  

 Jakob Dupont, M.D.

  

  

 377,163

  

  

  

 24,312

  

  

  

 475,883

  

 b. The selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 was ratified.

 Votes For

  

  

 Votes Against

  

  

 Votes Abstaining

  

  

 768,336

  

  

  

 107,471

  

  

  

 1,551

  

  
  

  
  

 SIGNATURES
 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

  

  

  

 Bolt Biotherapeutics, Inc.

  

  

  

  

 Date:

 June 11, 2026

 By:

 /s/ William P. Quinn

  

  

  

 William P. Quinn
President, Chief Executive Officer and Chief Financial Officer
 (Principal Executive and Financial Officer)